4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide has been researched along with Compensatory Hyperinsulinemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, M; Funaki, M; Hou, H; Hu, X; Li, Q; Liu, Y; Nakaya, Y; Shen, Q; Wu, Q; Xiao, J; Yin, W; Zhang, C | 1 |
| Hara, T; Kusunoki, M; Miyata, T; Nakamura, T; Nakaya, Y; Ogawa, H; Sakakibara, F; Sakamoto, S; Storlien, LH; Tsutsumi, K | 1 |
2 other study(ies) available for 4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide and Compensatory Hyperinsulinemia
| Article | Year |
|---|---|
NO-1886 suppresses diet-induced insulin resistance and cholesterol accumulation through STAT5-dependent upregulation of IGF1 and CYP7A1.
Topics: Animal Feed; Animals; Benzamides; Cell Line, Tumor; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Cholesterol, HDL; Cholesterol, LDL; Dietary Fats; Drug Administration Schedule; Humans; Hyperglycemia; Hyperinsulinism; Hypolipidemic Agents; Insulin Resistance; Insulin-Like Growth Factor I; Liver; Male; Organophosphorus Compounds; STAT5 Transcription Factor; Swine; Swine, Miniature; Up-Regulation | 2010 |
The lipoprotein lipase activator, NO-1886, suppresses fat accumulation and insulin resistance in rats fed a high-fat diet.
Topics: Adipose Tissue; Animals; Benzamides; Blood Glucose; Dietary Fats; Enzyme Activation; Fatty Acids, Nonesterified; Glucose Clamp Technique; Hyperinsulinism; Hypolipidemic Agents; Infusions, Intravenous; Insulin; Insulin Resistance; Lipoprotein Lipase; Male; Myocardium; Organophosphorus Compounds; Rats; Rats, Sprague-Dawley; Triglycerides | 2000 |